HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology7495 papers

Multiple myeloma

Last edited: 4/23/2026

Overview

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, leading to bone lesions, hypercalcemia, renal failure, and immunodeficiency. Recent advancements include innovative therapies targeting BCMA and CD38, achieving deeper remissions 1 7 77.

Diagnosis

Serum and Urine Protein Electrophoresis: Essential for detecting monoclonal proteins 11 61.

Bone Marrow Biopsy: Confirms plasma cell infiltration ≥30% 4 11.

Cytogenetic Testing: Identifies high-risk genetic abnormalities (e.g., t(4;14), del(17p)) 40 52.

Imaging: MRI and PET/CT for assessing bone lesions and extramedullary disease 33 63.

Measurable Residual Disease (MRD) Assessment: Utilizes multiparametric flow cytometry for post-treatment monitoring 8 14.

Management

First-Line Therapy: Triplet regimens often include proteasome inhibitors (e.g., bortezomib), immunomodulatory drugs (e.g., lenalidomide), and corticosteroids (e.g., dexamethasone) 44 55.

CAR-T Cell Therapy: For relapsed or refractory cases, particularly with BCMA-targeted therapies like teclistamab and ide-cel 6 7 73.

Bispecific Antibodies: Teclistamab and elranatamab targeting BCMA and CD3 for aggressive relapsed/refractory disease 1 77.

Bone Modifying Agents: Bisphosphonates to prevent skeletal complications 16.

Supportive Care: Management of pain, infections, and renal complications; consider palliative radiotherapy for bone pain 3 4.

Special Populations

Elderly Patients: Consider frailty scores (e.g., KG-7) for treatment decisions 44.

Comorbidities: Cardiovascular monitoring essential, especially with proteasome inhibitors 9 59.

Pregnancy: Limited data; treatment typically deferred until postpartum 24.

Pediatrics: Rare; management tailored to individual cases with supportive care 24.

Key Recommendations

Use of BCMA-targeted Therapies: Employ BCMA-targeted CAR-T cells (e.g., ide-cel) and bispecific antibodies (e.g., teclistamab) for patients with relapsed or refractory multiple myeloma (Evidence: Strong 6 7 73).

MRD Assessment Post-Treatment: Incorporate MRD assessment using flow cytometry to guide treatment decisions and monitor response (Evidence: Moderate 8 14).

Bisphosphonate Use: Administer bisphosphonates to prevent skeletal-related events in all patients with multiple myeloma (Evidence: Moderate 16).

Cardiovascular Monitoring: Regularly monitor cardiovascular health, particularly in patients receiving proteasome inhibitors (Evidence: Moderate 9 59).

Frailty Assessment in Elderly: Evaluate frailty using tools like KG-7 before initiating intensive therapies in elderly patients (Evidence: Moderate 44).

References

Showing 100 most recent of 6795 indexed papers.

1 . Two Drugs, One Stunning Myeloma Result. Cancer discovery 2026. link 2 Derman B, Jijun Liu J, Bouchard N, Figg L, LaPorte J, Goorha S et al.. Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers. Current medical research and opinion 2026. link 3 Rudzianskiene M, Inciura A, Gerbutavicius R, Rudzianskas V, Ugenskiene R, Paukstaitiene R et al.. The influence of polymorphisms in cytokine genes on pain and response to palliative radiotherapy in multiple myeloma patients: prospective observational study. Scandinavian journal of pain 2026. link 4 Ehara J, Sagara A, Ishida K, Yoshimi T, Takahashi N, Hosoya O. A Cross-sectional Exploratory Study on Symptom Correlations in Multiple Myeloma Patients During Initial Treatment Using the Edmonton Symptom Assessment System. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2026. link 5 Shahid H, Haseeb A, Iftikhar A, Sial F. Trends in mortality of renal failure in adult multiple myeloma patients: a CDC data analysis (1999-2020). International urology and nephrology 2026. link 6 Huynh THN, Clampitt BA, Chose CM, Nester MD, Joyce DM, Binitie OT et al.. Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma. The Journal of the American Academy of Orthopaedic Surgeons 2026. link 7 Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A et al.. Genomics Define Malignant Transformation in Myeloma Precursor Conditions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026. link 8 Deutsch-Biedermann K, Hefler-Frischmuth K, Gruber J, Kimbacher C, Herbring I, Machherndl-Spandl S et al.. Implementation of a one-tube flow cytometry panel for measurable residual disease detection in multiple myeloma patients in clinical routine. Cytometry. Part B, Clinical cytometry 2026. link 9 Tentolouris A, Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Duque ER, Dimopoulos MA et al.. Cardiovascular Safety of Carfilzomib in Patients with Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 2026. link 10 Iriyama N, Nakayama H, Nakagawa M, Takahata A, Sato E, Takano M et al.. Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group. International journal of hematology 2026. link 11 Puttkammer JR, Barreto JN, Jensen CJ, Nedved AN, Wilson-Miller JL, Cole KC et al.. Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization. JCO oncology practice 2026. link 12 Richardson T, Mai E, Menis E, Benner A, Tichy D, Miah K et al.. Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial. European journal of haematology 2026. link 13 Gao J, Qu X, Li M, Jia P, Cheng G, Yin J. Discovery of Y502-2304, a potent c-Myc G-quadruplex stabilizer for the treatment of multiple myeloma. European journal of medicinal chemistry 2026. link 14 O'Brien A, Mykytiv V, O'Halloran F. Enhanced Detection of Multiple Myeloma Cells by Next-Generation Flow Cytometry Following Density Gradient Medium Separation. European journal of haematology 2026. link 15 Xiang X, Yang R, Li J, Su B, Xu Z, An Y. Machine learning-assisted prognosis of multiple myeloma side population cells via SRGs and OCLR stemness index. Computer methods and programs in biomedicine 2026. link 16 Gal ZT, Wetzel EA, Nahed BV, Saylor PJ, Hirsch JA, Marciscano AE et al.. Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis. The spine journal : official journal of the North American Spine Society 2026. link 17 Wang Z, Wang G, Liu Y, Zhao Y, Guo S, Yang Y et al.. Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy. Journal for immunotherapy of cancer 2026. link 18 Lee HC, Yang C, Liu YH, Mu F, Wang J, Goble J et al.. Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care. Journal of medical economics 2026. link 19 Gavriatopoulou M, Manganas S, Ntanasis-Stathopoulos I, Dimopoulos MA. SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell. Clinical lymphoma, myeloma & leukemia 2026. link 20 Sachpekidis C, Hajiyianni M, Grözinger M, Piller M, Kopp-Schneider A, Mai EK et al.. Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the . European journal of nuclear medicine and molecular imaging 2026. [link 21 Mazof CJ, Natarajan V, Vrattos A, Shah P, Lansigan F, Hong J. Rising Prevalence of Central Nervous System Involvement in Multiple Myeloma: A 2012-2020 National Inpatient Sample (NIS) Analysis in the United States. Clinical lymphoma, myeloma & leukemia 2026. link 22 Shen Y, Benlabiod C, Watson E, Gurashi K, Fower A, Rodriguez-Romera A et al.. comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders. Cell stem cell 2026. link 23 Kier MW, Baldwin E, Truong TT, Sheng T, Diniz MA, Port JH et al.. Acute oncology hospital care at home for post-chemotherapy monitoring. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026. link 24 Junkins A, Wen W, Lipworth L, Han X, Munro H, Mumma MT et al.. Social determinants of health associated with multiple myeloma incidence and survival among a low-income cohort in the Southeastern U.S. Hematology (Amsterdam, Netherlands) 2026. link 25 Oliveira-Cardoso ÉA, Tabuzo VC, Andreossi VF, Oliveira MAS, Santos JHC, Lotério LS et al.. Psychosocial Functioning, Quality of Life, Depressive Symptoms, and Meaning in Life in Older Adults with Multiple Myeloma: A Cross-Sectional Study. International journal of environmental research and public health 2026. link 26 Jin C, Li J, Kim Y, Kim K, Hinterdorfer P, Kang S et al.. Anti-CD38 VLRB-Fc antibodies from transgenic tobacco exhibit potent anti-myeloma activity in vitro and in vivo. International journal of biological macromolecules 2026. link 27 Mohty M, Malard F, Facon T, Harousseau JL. Toward a cure for multiple myeloma within a decade. Blood cancer journal 2026. link 28 Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A et al.. Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. Journal for immunotherapy of cancer 2026. link 29 Cebulla N, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L et al.. Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans. Journal of the peripheral nervous system : JPNS 2026. link 30 Luo HL, Ding H, Chen F, Wang Y, Zhou L, Ye P et al.. Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry. Clinica chimica acta; international journal of clinical chemistry 2026. link 31 Li J, Li S, Al Faruque H, Kopeček J, Sborov DW, Yang J. CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma. Biomaterials 2026. link 32 Strotmann A, Leitner T, Mazzeo P, Evers G, Pohlmann A, Eisfeld C et al.. Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis. Clinical lymphoma, myeloma & leukemia 2026. link 33 Tokuhira M, Nakayama H, Toyama K, Takano M, Iriyama N, Takahata A et al.. Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database. International journal of hematology 2026. link 34 Miller KC, Usmani SZ. First-line Therapy in Newly Diagnosed Multiple Myeloma. Blood cancer discovery 2026. link 35 Aliyeva T, Alamy H, Ibrahim Ahmad FA, Natche J, Shah H, Shelar V et al.. The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Current research in translational medicine 2026. link 36 Cardus O, Mañé Pujol J, de Daniel A, Moreno DF, Oliveira TGM, Battram AM et al.. Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. Journal for immunotherapy of cancer 2026. link 37 Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P et al.. Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. Blood 2026. link 38 Mirshahvalad SA, Alghamdi A, Chavoshi M, Felder C, Metser U, Kukreti V et al.. Prognostic Value of [ 18 F]FDG PET/CT in Multiple Myeloma Patients at the Time of Initial Diagnosis. Clinical nuclear medicine 2026. link 39 Te Velde JP, Zijlstra H, Pierik RJB, Shankar GM, van Royen BJ, Kempen DHR et al.. Is surgery for multiple myeloma-related spinal involvement associated with higher blood loss compared to spinal metastases?. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2026. link 40 Yang C, Liu X, Li Y, Xiao J, Zhang C, Zhao N et al.. A comprehensive analysis of common cytogenetic abnormalities in multiple myeloma: from basic research to clinical applications. Pathology 2026. link 41 Jin Y, Cheng X, Zhang X, Shi Q, Zhu Y, Li J et al.. Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. Blood advances 2026. link 42 Wang G, Gao X, Zhang H, Hu K, Feng Q, Liu Y et al.. METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation. Oncogene 2026. link 43 Han S, Haertle L, Munawar U, Truger M, Hainold AS, Lee CY et al.. Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma. Clinical epigenetics 2026. link 44 Lee JY, Kim SA, Koh Y, Yhim HY, Lee GW, Min CK et al.. Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study. Cancer research and treatment 2026. link 45 Guinea-Pérez J, Uribe S, Peluso S, Castellani G, Nanni C, Álvarez F. Mask-aware foundational-model embeddings for 18F-FDG-PET/CT prognosis in multiple myeloma. Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society 2026. link 46 Vaxman I, Zamir I, Cohen I, Fridberg G, Shragai T, Trestman S et al.. The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study. Hematological oncology 2026. link 47 Yu T, Chen M, Huang B, Liu J, Li X, Gu J et al.. Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma. Archives of medical research 2026. link 48 Shah Z, Anderson CM, McCormick KD, Vallejo C, Duncan W, Hu C et al.. Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma. CPT: pharmacometrics & systems pharmacology 2026. link 49 Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR et al.. Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant. British journal of haematology 2026. link 50 Kumar S, Jagannath S, Weisel KC, Rosiñol L, Leleu X, Dimopoulos MA et al.. Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma. Blood cancer journal 2026. link 51 Solis-Poblano JC, Itzmoyotl-Hernández MT, Pérez-Lozano U, García-Stivalet LA, López-Marthen JL, Silva-Ruacho R et al.. Multiple myeloma in Mexico: a retrospective study on long-term survival in a publicly insured cohort. Leukemia & lymphoma 2026. link 52 Zammar G, Augustson B, Moore E, Wellard C, Ashrafi E, Sidiqi H et al.. Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups. Clinical lymphoma, myeloma & leukemia 2026. link 53 Mutlu YG, Emre Ünsal Ş, Güleç B, Serin İ, Arslan Davulcu E, Sönmez GM et al.. The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History. Clinical lymphoma, myeloma & leukemia 2026. link 54 Gan X, Li L, Zhang L, Zheng Y, Niu T, Yu Z. Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma. Targeted oncology 2026. link 55 Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S et al.. Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026. link 56 Ailawadhi S, Anderson LD, Dhakal B, Shune L, Sborov DW, Hansen DK. Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clinical lymphoma, myeloma & leukemia 2026. link 57 Gu H, Dai Z, Huang X, Zhang E, Dai X, Chen H et al.. FAPα. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 58 Han D, Wolters EA, Arowolo FK, Salam SP, Irudhayanathan GM, Mendu DR. Unmasking complex polymerization interferences in multiple myeloma diagnostics: A case study. Clinica chimica acta; international journal of clinical chemistry 2026. link 59 Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N et al.. Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy. British journal of haematology 2026. link 60 Milanesio M, Olmedo J, Caeiro G, Basquiera AL. Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report. Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) 2026. link 61 Chen Y, You L, Zhu L, Yin X, Yao Q, Ding S et al.. Evaluation of iMS-IP assay for the detection and typing of monoclonal immunoglobulins. Clinica chimica acta; international journal of clinical chemistry 2026. link 62 Hur JY, Park HS, Choi Y, Park H, Lee YE, Jeong J et al.. Long-term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma. In vivo (Athens, Greece) 2026. link 63 Grözinger M, Schlanke M, Gröne J, Erdmann S, Hajiyianni M, Poos AM et al.. Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma. Leukemia 2026. link 64 Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M et al.. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood advances 2026. link 65 Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S et al.. Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH). Blood 2026. link 66 Lu L, Lin S, Chen Y, Huang Y. Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database. Hematology (Amsterdam, Netherlands) 2026. link 67 Wang YC, Li PH, Lin CH, Su YC, Teng CJ. Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study. Targeted oncology 2026. link 68 Ronchetti D, Traini V, Silvestris I, Fabbiano G, Devecchi A, Torricelli F et al.. Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma. Journal of cellular and molecular medicine 2026. link 69 Gay F, Buda G, Petrucci MT, Bolli N, Cea M, Derudas D et al.. Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. ESMO open 2026. link 70 Wright BD, Houson HA, Fernandez S, Gultekin K, McConathy JE, Giri S et al.. PET Imaging of CD38 and IND enabling studies of . Molecular imaging and biology 2026. [link 71 Zhao S, Wang Y, Jia J, Bu Q, Chen W. Risk factors for venous thromboembolism in newly diagnosed multiple myeloma patients based on thrombosis prophylaxis. Annals of hematology 2026. link 72 Sáez-Marín AJ, Hernandez-Ibarbu G, Alba LM, Babio RM, Tamayo A, Fonseca AC et al.. A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years. Clinical lymphoma, myeloma & leukemia 2026. link 73 Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C et al.. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine 2026. link 74 Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R et al.. Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials. Journal of the National Cancer Institute 2026. link 75 Lin J, He J, Cai Z, He D. MRD contamination in peripheral blood autologous stem cell grafts: implications for relapse and prognosis in multiple myeloma. Leukemia & lymphoma 2026. link 76 Gasparin F, Tietje MR, Katab E, Nurdinova A, Yuan T, Chmyrov A et al.. Label-free protein-structure-sensitive live-cell microscopy for patient-specific assessment of myeloma therapy. Nature biomedical engineering 2026. link 77 Germans SK, Zhang B, Weinberg O. Secondary neoplasms following treatment for multiple myeloma. Seminars in diagnostic pathology 2026. link 78 Klomberg KM, Gelderloos M, Kooistra HAM, Nijland M, de Bock GH, Huls GA et al.. Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years. Clinical lymphoma, myeloma & leukemia 2026. link 79 Rodríguez-Otero P, Moreau P, Mateos MV, Krauth MT, Rasche L, Kastritis E et al.. European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 2026. link 80 Hughes PR, Shreve NE, Bloecher PA. Multiple Myeloma: Diagnosis and Treatment. American family physician 2026. link 81 Zheng M, Zhang K, Mu H, Liu Q, Ge S, Shan Y et al.. CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities. Molecular pharmaceutics 2026. link 82 Shen X, Yu J, Cheng X, Yao Y, Jin Y, Shi Q et al.. Prognostic Effect of Sarcopenia and Nutritional Factors on Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Exploratory Study. Journal of cachexia, sarcopenia and muscle 2026. link 83 Cholujova D, Csicsatkova N, Valuskova Z, Suroviakova K, Marinkovicova ME, Strizova A et al.. Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany) 2026. link 84 Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R et al.. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert review of pharmacoeconomics & outcomes research 2026. link 85 Chakraborty R, Mohyuddin GR. Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of ≥100. Blood 2026. link 86 Mosquera Jiménez DJ, Carballo L, Baldoncini M, Sevlever G, Echavarría Demichelis M. Multiple myeloma mimicking olfactory sulcus meningioma: Case report and literature review. Neurocirugia 2026. link 87 Gramegna D, Mondelli P, Pappagallo SA, Gargano G, Vegliante MC, Quinto AM et al.. Cutting-Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma. Hematological oncology 2026. link 88 Kundu N, Mahalik A, Khan D, Kumar R. 18 F-FDG PET/CT Findings in a Case of Plasmablastic Myeloma: A Rare Entity. Clinical nuclear medicine 2026. link 89 Giuliani N, Dalla Palma B, Notarfranchi L. Advances in the pathophysiology and treatment of anaemia in multiple myeloma. Current opinion in hematology 2026. link 90 Michaud TL, Shih YH, Ji M, Huber J, Zhang W, Wang M et al.. Differential life expectancies and life years lost associated with multiple myeloma in the United States: a simulation modeling study. The oncologist 2026. link 91 Piron B, Rodrigo L, Tessoulin B, Gastinne T, Dubruille V, Letailleur V et al.. Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies. Clinical lymphoma, myeloma & leukemia 2026. link 92 Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L et al.. Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study. Leukemia 2026. link 93 Lu P, Shangguan W, Qian W, Wu D, Li W, Huang J et al.. Noncanonical role of KDM5C in conferring bortezomib resistance via the PERK‒Nrf2 axis in multiple myeloma. Cell death & disease 2026. link 94 Haider I, Leong DP, Shahid O, Louzada M, McCurdy A, Pond GR et al.. Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Clinical lymphoma, myeloma & leukemia 2026. link 95 Kitamura A, Fujita S, Isono Y, Nakano T, Morino T, Tozuka K et al.. Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2026. link 96 Zhu Z, Li X, Chen X, Yuan X, Lin T, Li N. Etoposide + cytarabine plus granulocyte colony-stimulating factor mitigates daratumumab-associated impairment on stem cell mobilization in newly diagnosed multiple myeloma. Cytotherapy 2026. link 97 Nørgaard JN, Abildgaard N, Lysén A, Tsykunova G, Vangsted AJ, João C et al.. Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET). Clinical lymphoma, myeloma & leukemia 2026. link 98 Fogel L, Roney PC, Ahn J, Aleman A, Perez-Manon F, Arias-Orozco N et al.. Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience. Leukemia & lymphoma 2026. link 99 Zhang T, Cheng X, Jin Y, Zhang R, Shen X, Chen L et al.. Impact of CD34. Leukemia & lymphoma 2026. link 100 Ohlstrom DJ, Pilcher WC, Michaud ME, Acharya C, Satpathy S, Gonzalez-Kozlova E et al.. Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma. Blood cancer discovery 2026. link

Original source

[1]
Two Drugs, One Stunning Myeloma Result. Cancer discovery (2026)
[2]
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers. — Derman B, Jijun Liu J, Bouchard N, Figg L, LaPorte J, Goorha S et al. Current medical research and opinion (2026)
[3]
The influence of polymorphisms in cytokine genes on pain and response to palliative radiotherapy in multiple myeloma patients: prospective observational study. — Rudzianskiene M, Inciura A, Gerbutavicius R, Rudzianskas V, Ugenskiene R, Paukstaitiene R et al. Scandinavian journal of pain (2026)
[4]
A Cross-sectional Exploratory Study on Symptom Correlations in Multiple Myeloma Patients During Initial Treatment Using the Edmonton Symptom Assessment System. — Ehara J, Sagara A, Ishida K, Yoshimi T, Takahashi N, Hosoya O Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan (2026)
[5]
Trends in mortality of renal failure in adult multiple myeloma patients: a CDC data analysis (1999-2020). — Shahid H, Haseeb A, Iftikhar A, Sial F International urology and nephrology (2026)
[6]
Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma. — Huynh THN, Clampitt BA, Chose CM, Nester MD, Joyce DM, Binitie OT et al. The Journal of the American Academy of Orthopaedic Surgeons (2026)
[7]
Genomics Define Malignant Transformation in Myeloma Precursor Conditions. — Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026)
[8]
Implementation of a one-tube flow cytometry panel for measurable residual disease detection in multiple myeloma patients in clinical routine. — Deutsch-Biedermann K, Hefler-Frischmuth K, Gruber J, Kimbacher C, Herbring I, Machherndl-Spandl S et al. Cytometry. Part B, Clinical cytometry (2026)
[9]
Cardiovascular Safety of Carfilzomib in Patients with Multiple Myeloma. — Tentolouris A, Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Duque ER, Dimopoulos MA et al. Clinical lymphoma, myeloma & leukemia (2026)
[10]
Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group. — Iriyama N, Nakayama H, Nakagawa M, Takahata A, Sato E, Takano M et al. International journal of hematology (2026)
[11]
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization. — Puttkammer JR, Barreto JN, Jensen CJ, Nedved AN, Wilson-Miller JL, Cole KC et al. JCO oncology practice (2026)
[12]
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial. — Richardson T, Mai E, Menis E, Benner A, Tichy D, Miah K et al. European journal of haematology (2026)
[13]
Discovery of Y502-2304, a potent c-Myc G-quadruplex stabilizer for the treatment of multiple myeloma. — Gao J, Qu X, Li M, Jia P, Cheng G, Yin J European journal of medicinal chemistry (2026)
[14]
Enhanced Detection of Multiple Myeloma Cells by Next-Generation Flow Cytometry Following Density Gradient Medium Separation. — O'Brien A, Mykytiv V, O'Halloran F European journal of haematology (2026)
[15]
Machine learning-assisted prognosis of multiple myeloma side population cells via SRGs and OCLR stemness index. — Xiang X, Yang R, Li J, Su B, Xu Z, An Y Computer methods and programs in biomedicine (2026)
[16]
Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis. — Gal ZT, Wetzel EA, Nahed BV, Saylor PJ, Hirsch JA, Marciscano AE et al. The spine journal : official journal of the North American Spine Society (2026)
[17]
Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy. — Wang Z, Wang G, Liu Y, Zhao Y, Guo S, Yang Y et al. Journal for immunotherapy of cancer (2026)
[18]
Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care. — Lee HC, Yang C, Liu YH, Mu F, Wang J, Goble J et al. Journal of medical economics (2026)
[19]
SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell. — Gavriatopoulou M, Manganas S, Ntanasis-Stathopoulos I, Dimopoulos MA Clinical lymphoma, myeloma & leukemia (2026)
[20]
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [ — Sachpekidis C, Hajiyianni M, Grözinger M, Piller M, Kopp-Schneider A, Mai EK et al. European journal of nuclear medicine and molecular imaging (2026)
[21]
Rising Prevalence of Central Nervous System Involvement in Multiple Myeloma: A 2012-2020 National Inpatient Sample (NIS) Analysis in the United States. — Mazof CJ, Natarajan V, Vrattos A, Shah P, Lansigan F, Hong J Clinical lymphoma, myeloma & leukemia (2026)
[22]
comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders. — Shen Y, Benlabiod C, Watson E, Gurashi K, Fower A, Rodriguez-Romera A et al. Cell stem cell (2026)
[23]
Acute oncology hospital care at home for post-chemotherapy monitoring. — Kier MW, Baldwin E, Truong TT, Sheng T, Diniz MA, Port JH et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026)
[24]
Social determinants of health associated with multiple myeloma incidence and survival among a low-income cohort in the Southeastern U.S. — Junkins A, Wen W, Lipworth L, Han X, Munro H, Mumma MT et al. Hematology (Amsterdam, Netherlands) (2026)
[25]
Psychosocial Functioning, Quality of Life, Depressive Symptoms, and Meaning in Life in Older Adults with Multiple Myeloma: A Cross-Sectional Study. — Oliveira-Cardoso ÉA, Tabuzo VC, Andreossi VF, Oliveira MAS, Santos JHC, Lotério LS et al. International journal of environmental research and public health (2026)
[26]
Anti-CD38 VLRB-Fc antibodies from transgenic tobacco exhibit potent anti-myeloma activity in vitro and in vivo. — Jin C, Li J, Kim Y, Kim K, Hinterdorfer P, Kang S et al. International journal of biological macromolecules (2026)
[27]
Toward a cure for multiple myeloma within a decade. — Mohty M, Malard F, Facon T, Harousseau JL Blood cancer journal (2026)
[28]
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. — Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A et al. Journal for immunotherapy of cancer (2026)
[29]
Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans. — Cebulla N, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L et al. Journal of the peripheral nervous system : JPNS (2026)
[30]
Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry. — Luo HL, Ding H, Chen F, Wang Y, Zhou L, Ye P et al. Clinica chimica acta; international journal of clinical chemistry (2026)
[31]
CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma. — Li J, Li S, Al Faruque H, Kopeček J, Sborov DW, Yang J Biomaterials (2026)
[32]
Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis. — Strotmann A, Leitner T, Mazzeo P, Evers G, Pohlmann A, Eisfeld C et al. Clinical lymphoma, myeloma & leukemia (2026)
[33]
Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database. — Tokuhira M, Nakayama H, Toyama K, Takano M, Iriyama N, Takahata A et al. International journal of hematology (2026)
[34]
First-line Therapy in Newly Diagnosed Multiple Myeloma. — Miller KC, Usmani SZ Blood cancer discovery (2026)
[35]
The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. — Aliyeva T, Alamy H, Ibrahim Ahmad FA, Natche J, Shah H, Shelar V et al. Current research in translational medicine (2026)
[36]
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. — Cardus O, Mañé Pujol J, de Daniel A, Moreno DF, Oliveira TGM, Battram AM et al. Journal for immunotherapy of cancer (2026)
[37]
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. — Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P et al. Blood (2026)
[38]
Prognostic Value of [ 18 F]FDG PET/CT in Multiple Myeloma Patients at the Time of Initial Diagnosis. — Mirshahvalad SA, Alghamdi A, Chavoshi M, Felder C, Metser U, Kukreti V et al. Clinical nuclear medicine (2026)
[39]
Is surgery for multiple myeloma-related spinal involvement associated with higher blood loss compared to spinal metastases? — Te Velde JP, Zijlstra H, Pierik RJB, Shankar GM, van Royen BJ, Kempen DHR et al. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2026)
[40]
A comprehensive analysis of common cytogenetic abnormalities in multiple myeloma: from basic research to clinical applications. — Yang C, Liu X, Li Y, Xiao J, Zhang C, Zhao N et al. Pathology (2026)
[41]
Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. — Jin Y, Cheng X, Zhang X, Shi Q, Zhu Y, Li J et al. Blood advances (2026)
[42]
METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation. — Wang G, Gao X, Zhang H, Hu K, Feng Q, Liu Y et al. Oncogene (2026)
[43]
Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma. — Han S, Haertle L, Munawar U, Truger M, Hainold AS, Lee CY et al. Clinical epigenetics (2026)
[44]
Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study. — Lee JY, Kim SA, Koh Y, Yhim HY, Lee GW, Min CK et al. Cancer research and treatment (2026)
[45]
Mask-aware foundational-model embeddings for 18F-FDG-PET/CT prognosis in multiple myeloma. — Guinea-Pérez J, Uribe S, Peluso S, Castellani G, Nanni C, Álvarez F Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society (2026)
[46]
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study. — Vaxman I, Zamir I, Cohen I, Fridberg G, Shragai T, Trestman S et al. Hematological oncology (2026)
[47]
Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma. — Yu T, Chen M, Huang B, Liu J, Li X, Gu J et al. Archives of medical research (2026)
[48]
Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma. — Shah Z, Anderson CM, McCormick KD, Vallejo C, Duncan W, Hu C et al. CPT: pharmacometrics & systems pharmacology (2026)
[49]
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant. — Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR et al. British journal of haematology (2026)
[50]
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma. — Kumar S, Jagannath S, Weisel KC, Rosiñol L, Leleu X, Dimopoulos MA et al. Blood cancer journal (2026)
[51]
Multiple myeloma in Mexico: a retrospective study on long-term survival in a publicly insured cohort. — Solis-Poblano JC, Itzmoyotl-Hernández MT, Pérez-Lozano U, García-Stivalet LA, López-Marthen JL, Silva-Ruacho R et al. Leukemia & lymphoma (2026)
[52]
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups. — Zammar G, Augustson B, Moore E, Wellard C, Ashrafi E, Sidiqi H et al. Clinical lymphoma, myeloma & leukemia (2026)
[53]
The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History. — Mutlu YG, Emre Ünsal Ş, Güleç B, Serin İ, Arslan Davulcu E, Sönmez GM et al. Clinical lymphoma, myeloma & leukemia (2026)
[54]
Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma. — Gan X, Li L, Zhang L, Zheng Y, Niu T, Yu Z Targeted oncology (2026)
[55]
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline. — Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026)
[56]
Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable. — Ailawadhi S, Anderson LD, Dhakal B, Shune L, Sborov DW, Hansen DK Clinical lymphoma, myeloma & leukemia (2026)
[57]
FAPα — Gu H, Dai Z, Huang X, Zhang E, Dai X, Chen H et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026)
[58]
Unmasking complex polymerization interferences in multiple myeloma diagnostics: A case study. — Han D, Wolters EA, Arowolo FK, Salam SP, Irudhayanathan GM, Mendu DR Clinica chimica acta; international journal of clinical chemistry (2026)
[59]
Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy. — Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N et al. British journal of haematology (2026)
[60]
Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report. — Milanesio M, Olmedo J, Caeiro G, Basquiera AL Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) (2026)
[61]
Evaluation of iMS-IP assay for the detection and typing of monoclonal immunoglobulins. — Chen Y, You L, Zhu L, Yin X, Yao Q, Ding S et al. Clinica chimica acta; international journal of clinical chemistry (2026)
[62]
Long-term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma. — Hur JY, Park HS, Choi Y, Park H, Lee YE, Jeong J et al. In vivo (Athens, Greece) (2026)
[63]
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma. — Grözinger M, Schlanke M, Gröne J, Erdmann S, Hajiyianni M, Poos AM et al. Leukemia (2026)
[64]
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. — Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M et al. Blood advances (2026)
[65]
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH). — Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S et al. Blood (2026)
[66]
Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database. — Lu L, Lin S, Chen Y, Huang Y Hematology (Amsterdam, Netherlands) (2026)
[67]
Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study. — Wang YC, Li PH, Lin CH, Su YC, Teng CJ Targeted oncology (2026)
[68]
Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma. — Ronchetti D, Traini V, Silvestris I, Fabbiano G, Devecchi A, Torricelli F et al. Journal of cellular and molecular medicine (2026)
[69]
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. — Gay F, Buda G, Petrucci MT, Bolli N, Cea M, Derudas D et al. ESMO open (2026)
[70]
PET Imaging of CD38 and IND enabling studies of [ — Wright BD, Houson HA, Fernandez S, Gultekin K, McConathy JE, Giri S et al. Molecular imaging and biology (2026)
[71]
Risk factors for venous thromboembolism in newly diagnosed multiple myeloma patients based on thrombosis prophylaxis. — Zhao S, Wang Y, Jia J, Bu Q, Chen W Annals of hematology (2026)
[72]
A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years. — Sáez-Marín AJ, Hernandez-Ibarbu G, Alba LM, Babio RM, Tamayo A, Fonseca AC et al. Clinical lymphoma, myeloma & leukemia (2026)
[73]
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. — Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C et al. The New England journal of medicine (2026)
[74]
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials. — Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R et al. Journal of the National Cancer Institute (2026)
[75]
MRD contamination in peripheral blood autologous stem cell grafts: implications for relapse and prognosis in multiple myeloma. — Lin J, He J, Cai Z, He D Leukemia & lymphoma (2026)
[76]
Label-free protein-structure-sensitive live-cell microscopy for patient-specific assessment of myeloma therapy. — Gasparin F, Tietje MR, Katab E, Nurdinova A, Yuan T, Chmyrov A et al. Nature biomedical engineering (2026)
[77]
Secondary neoplasms following treatment for multiple myeloma. — Germans SK, Zhang B, Weinberg O Seminars in diagnostic pathology (2026)
[78]
Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years. — Klomberg KM, Gelderloos M, Kooistra HAM, Nijland M, de Bock GH, Huls GA et al. Clinical lymphoma, myeloma & leukemia (2026)
[79]
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma. — Rodríguez-Otero P, Moreau P, Mateos MV, Krauth MT, Rasche L, Kastritis E et al. Clinical lymphoma, myeloma & leukemia (2026)
[80]
Multiple Myeloma: Diagnosis and Treatment. — Hughes PR, Shreve NE, Bloecher PA American family physician (2026)
[81]
CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities. — Zheng M, Zhang K, Mu H, Liu Q, Ge S, Shan Y et al. Molecular pharmaceutics (2026)
[82]
Prognostic Effect of Sarcopenia and Nutritional Factors on Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Exploratory Study. — Shen X, Yu J, Cheng X, Yao Y, Jin Y, Shi Q et al. Journal of cachexia, sarcopenia and muscle (2026)
[83]
Anti-myeloma activity of the CXCR4 antagonist WZ811. — Cholujova D, Csicsatkova N, Valuskova Z, Suroviakova K, Marinkovicova ME, Strizova A et al. Journal of molecular medicine (Berlin, Germany) (2026)
[84]
Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. — Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R et al. Expert review of pharmacoeconomics & outcomes research (2026)
[85]
Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of ≥100. — Chakraborty R, Mohyuddin GR Blood (2026)
[86]
Multiple myeloma mimicking olfactory sulcus meningioma: Case report and literature review. — Mosquera Jiménez DJ, Carballo L, Baldoncini M, Sevlever G, Echavarría Demichelis M Neurocirugia (2026)
[87]
Cutting-Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma. — Gramegna D, Mondelli P, Pappagallo SA, Gargano G, Vegliante MC, Quinto AM et al. Hematological oncology (2026)
[88]
18 F-FDG PET/CT Findings in a Case of Plasmablastic Myeloma: A Rare Entity. — Kundu N, Mahalik A, Khan D, Kumar R Clinical nuclear medicine (2026)
[89]
Advances in the pathophysiology and treatment of anaemia in multiple myeloma. — Giuliani N, Dalla Palma B, Notarfranchi L Current opinion in hematology (2026)
[90]
Differential life expectancies and life years lost associated with multiple myeloma in the United States: a simulation modeling study. — Michaud TL, Shih YH, Ji M, Huber J, Zhang W, Wang M et al. The oncologist (2026)
[91]
Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies. — Piron B, Rodrigo L, Tessoulin B, Gastinne T, Dubruille V, Letailleur V et al. Clinical lymphoma, myeloma & leukemia (2026)
[92]
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study. — Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L et al. Leukemia (2026)
[93]
Noncanonical role of KDM5C in conferring bortezomib resistance via the PERK‒Nrf2 axis in multiple myeloma. — Lu P, Shangguan W, Qian W, Wu D, Li W, Huang J et al. Cell death & disease (2026)
[94]
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL). — Haider I, Leong DP, Shahid O, Louzada M, McCurdy A, Pond GR et al. Clinical lymphoma, myeloma & leukemia (2026)
[95]
Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma. — Kitamura A, Fujita S, Isono Y, Nakano T, Morino T, Tozuka K et al. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026)
[96]
Etoposide + cytarabine plus granulocyte colony-stimulating factor mitigates daratumumab-associated impairment on stem cell mobilization in newly diagnosed multiple myeloma. — Zhu Z, Li X, Chen X, Yuan X, Lin T, Li N Cytotherapy (2026)
[97]
Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET). — Nørgaard JN, Abildgaard N, Lysén A, Tsykunova G, Vangsted AJ, João C et al. Clinical lymphoma, myeloma & leukemia (2026)
[98]
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience. — Fogel L, Roney PC, Ahn J, Aleman A, Perez-Manon F, Arias-Orozco N et al. Leukemia & lymphoma (2026)
[99]
Impact of CD34 — Zhang T, Cheng X, Jin Y, Zhang R, Shen X, Chen L et al. Leukemia & lymphoma (2026)
[100]
Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma. — Ohlstrom DJ, Pilcher WC, Michaud ME, Acharya C, Satpathy S, Gonzalez-Kozlova E et al. Blood cancer discovery (2026)

Share:Twitter Reddit LinkedIn